

Claus Michael RÄ¶del

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1153565/publications.pdf>

Version: 2024-02-01

74
papers

2,681
citations

218677

26
h-index

189892

50
g-index

76
all docs

76
docs citations

76
times ranked

3643
citing authors

#	ARTICLE	IF	CITATIONS
1	Patterns of care analysis for salivary gland cancer: a survey within the German Society of Radiation Oncology (DEGRO) and recommendations for daily practice. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 123-134.	2.0	6
2	Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial. <i>European Journal of Nutrition</i> , 2022, 61, 477-487.	3.9	16
3	Risk stratification by anamnesis increases SARS-CoV-2 test efficiency in cancer patients. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 354-360.	2.0	0
4	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2022, 167, 300-307.	0.6	5
5	Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. <i>Cancer Cell</i> , 2022, 40, 168-184.e13.	16.8	117
6	Effects of iodinated contrast agent on HU-based dose calculation and dose delivered in iridium-192 high-dose-rate brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2022, 14, 80-86.	0.9	0
7	C-Reactive Protein to Albumin Ratio as Prognostic Marker in Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy. <i>Biomedicines</i> , 2022, 10, 598.	3.2	10
8	Neoadjuvant Chemoradiotherapy for Oral Cavity Cancer: Predictive Factors for Response and Interim Analysis of the Prospective INVERT-Trial. <i>Frontiers in Oncology</i> , 2022, 12, 817692.	2.8	4
9	ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group. <i>Clinical and Translational Radiation Oncology</i> , 2022, 34, 99-106.	1.7	7
10	Image-guided high-dose-rate brachytherapy for rectal cancer: technical note and first clinical experience on an organ-preserving approach. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 654-662.	2.0	10
11	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2022, 171, 91-100.	0.6	4
12	Factors Associated with Hemorrhage of Melanoma Brain Metastases after Stereotactic Radiosurgery in the Era of Targeted/Immune Checkpoint Inhibitor Therapies. <i>Cancers</i> , 2022, 14, 2391.	3.7	6
13	Advances in nanotechnology-based platforms for survivin-targeted drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 733-754.	5.0	10
14	Radioimmunotherapy: future prospects from the perspective of brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 458-467.	0.9	6
15	Individualized mould-based high-dose-rate brachytherapy for perinasal skin tumors: technique evaluation from a dosimetric point of view. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 179-187.	0.9	2
16	Interstitial multicatheter HDR-brachytherapy as accelerated partial breast irradiation after second breast-conserving surgery for locally recurrent breast cancer. <i>Journal of Radiation Research</i> , 2021, 62, 465-472.	1.6	6
17	Patterns of care, toxicity and outcome in the treatment of salivary gland carcinomas: long-term experience from a tertiary cancer center. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 4411-4421.	1.6	4
18	Re-irradiation with concurrent and maintenance nivolumab in locally recurrent and inoperable squamous cell carcinoma of the head and neck: A single-center cohort study. <i>Clinical and Translational Radiation Oncology</i> , 2021, 28, 71-78.	1.7	6

#	ARTICLE	IF	CITATIONS
19	A Spatial and Functional Interaction of a Heterotetramer Survivinâ€“DNA-PKcs Complex in DNA Damage Response. <i>Cancer Research</i> , 2021, 81, 2304-2317.	0.9	8
20	Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer. <i>Cancers</i> , 2021, 13, 5748.	3.7	11
21	High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up. <i>Frontiers in Oncology</i> , 2021, 11, 770959.	2.8	3
22	The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper. <i>Radiotherapy and Oncology</i> , 2020, 142, 6-16.	0.6	12
23	Maintenance of Energy Homeostasis during Calorically Restricted Ketogenic Diet and Fasting-MR-Spectroscopic Insights from the ERGO2 Trial. <i>Cancers</i> , 2020, 12, 3549.	3.7	9
24	Targeted Natural Killer Cellâ€“Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial. <i>Clinical Cancer Research</i> , 2020, 26, 5368-5379.	7.0	42
25	Sarcopenia Is Associated With Hematologic Toxicity During Chemoradiotherapy in Patients With Anal Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1576.	2.8	5
26	Fractionation-Dependent Radiosensitization by Molecular Targeting of Nek1. <i>Cells</i> , 2020, 9, 1235.	4.1	5
27	Management of anal cancer patients â€“ a pattern of care analysis in German-speaking countries. <i>Radiation Oncology</i> , 2020, 15, 122.	2.7	5
28	ERGO2: A Prospective, Randomized Trial of Calorie-Restricted Ketogenic Diet and Fasting in Addition to Reirradiation for Malignant Glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 987-995.	0.8	46
29	Comparison of GeneChip, nCounter, and Real-Time PCRâ€“Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 801-810.	2.8	10
30	Acute organ toxicity correlates with better clinical outcome after chemoradiotherapy in patients with anal carcinoma. <i>Radiotherapy and Oncology</i> , 2020, 149, 168-173.	0.6	4
31	Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa137.	0.7	2
32	Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2). <i>Oncologist</i> , 2019, 24, e1341-e1350.	3.7	28
33	Association of Polo-Like Kinase 3 and PhosphoT273 Caspase 8 Levels With Disease-Related Outcomes Among Cervical Squamous Cell Carcinoma Patients Treated With Chemoradiation and Brachytherapy. <i>Frontiers in Oncology</i> , 2019, 9, 742.	2.8	5
34	Organ Preservation in Rectal Cancer: The Patients' Perspective. <i>Frontiers in Oncology</i> , 2019, 9, 318.	2.8	44
35	Characterization of the tumor immune micromilieu and its interference with outcome after concurrent chemoradiation in patients with oropharyngeal carcinomas. <i>Oncolmmunology</i> , 2019, 8, 1614858.	4.6	24
36	A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection. <i>Clinical Cancer Research</i> , 2019, 25, 1505-1516.	7.0	67

#	ARTICLE	IF	CITATIONS
37	Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 126-137.	7.4	12
38	Second in-field re-irradiation with a resulting cumulative equivalent dose (EQD2 max) of >180% Gy for patients with recurrent head and neck cancer. <i>Head and Neck</i> , 2019, 41, E48-E54.	2.0	4
39	Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DTK/ROG analysis. <i>Radiotherapy and Oncology</i> , 2018, 127, 121-127.	0.6	37
40	Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 214-221.	0.6	7
41	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. <i>Radiotherapy and Oncology</i> , 2018, 127, 27-35.	0.6	17
42	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 125-131.	0.6	24
43	Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , 2018, 142, 1911-1925.	5.1	50
44	CT-guided interstitial HDR-brachytherapy for recurrent glioblastoma multiforme: a 20-year single-institute experience. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 1171-1179.	2.0	10
45	Patterns of care analysis for head & neck cancer of unknown primary site: a survey inside the German society of radiation oncology (DEGRO). <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 750-758.	2.0	13
46	Repeated in-field radiosurgery for locally recurrent brain metastases: Feasibility, results and survival in a heavily treated patient cohort. <i>PLoS ONE</i> , 2018, 13, e0198692.	2.5	47
47	Cost analysis of a wait-and-see strategy after radiochemotherapy in distal rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 985-990.	2.0	5
48	Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 305-314.	2.0	7
49	Human papilloma virus load and PD-1/PD-L1, CD8 ⁺ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy. <i>Oncolmmunology</i> , 2017, 6, e1288331.	4.6	79
50	A clinical example of extreme dose exposure for an implanted cardioverter-defibrillator. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 756-760.	2.0	3
51	Diagnostic and treatment modalities for patients with cervical lymph node metastases of unknown primary site – current status and challenges. <i>Radiation Oncology</i> , 2017, 12, 82.	2.7	33
52	Basics of Radiation Biology When Treating Hyperproliferative Benign Diseases. <i>Frontiers in Immunology</i> , 2017, 8, 519.	4.8	26
53	Peripheral Leukocytosis Is Inversely Correlated with Intratumoral CD8 ⁺ T-Cell Infiltration and Associated with Worse Outcome after Chemoradiotherapy in Anal Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1225.	4.8	29
54	Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of caspase-8. <i>Cell Research</i> , 2016, 26, 914-934.	12.0	35

#	ARTICLE	IF	CITATIONS
55	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2016, 121, 364-373.	0.6	130
56	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(+) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. <i>Clinical Cancer Research</i> , 2016, 22, 2639-2649.	7.0	127
57	Hedgehog pathway inhibitor in combination with radiation therapy for basal cell carcinomas of the head and neck. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 25-31.	2.0	22
58	Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy. <i>Oncotarget</i> , 2016, 7, 53339-53349.	1.8	12
59	A 4-miRNA signature predicts the therapeutic outcome of glioblastoma. <i>Oncotarget</i> , 2016, 7, 45764-45775.	1.8	35
60	Definitive, Preoperative, and Palliative Radiation Therapy of Esophageal Cancer. <i>Visceral Medicine</i> , 2015, 31, 347-353.	1.3	8
61	The SMAC mimetic BV6 sensitizes colorectal cancer cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis. <i>Radiation Oncology</i> , 2015, 10, 198.	2.7	27
62	The role of recent nanotechnology in enhancing the efficacy of radiation therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1856, 130-143.	7.4	46
63	Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer. <i>Oncolmmunology</i> , 2014, 3, e27403.	4.6	61
64	Identifying the Most Predictive Post-Chemoradiation TRG System for Rectal Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	9
65	Organ-Sparing Multimodality Treatment for Muscle-Invasive Bladder Cancer: Can We Continue to Ignore the Evidence?. <i>Journal of Clinical Oncology</i> , 2014, 32, 3787-3788.	1.6	18
66	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2014, 113, 317-323.	0.6	141
67	Targeting by cmHsp70.1-antibody coated and survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells. <i>Journal of Controlled Release</i> , 2013, 172, 201-206.	9.9	49
68	Failure of Downregulation of Survivin Following Neoadjuvant Radiochemotherapy in Rectal Cancer Is Associated with Distant Metastases and Shortened Survival. <i>Clinical Cancer Research</i> , 2011, 17, 1623-1631.	7.0	37
69	15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. <i>Anticancer Research</i> , 2011, 31, 985-90.	1.1	75
70	Radiation Therapy for Early Stages of Morbus Ledderhose. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 24-29.	2.0	56
71	Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: Survivin as a radioresistance factor. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 1341-1347.	0.8	146
72	Combined-Modality Treatment and Selective Organ Preservation in Invasive Bladder Cancer: Long-Term Results. <i>Journal of Clinical Oncology</i> , 2002, 20, 3061-3071.	1.6	602

#	ARTICLE	IF	CITATIONS
73	Radiotherapy is an Effective Treatment for High-Risk T1-Bladder Cancer. <i>Strahlentherapie Und Onkologie</i> , 2001, 177, 82-88.	2.0	23
74	Preoperative Radiation with Concurrent 5-Fluorouracil for Locally Advanced T4-Primary Rectal Cancer. <i>Strahlentherapie Und Onkologie</i> , 2000, 176, 161-167.	2.0	70